Multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-binding cassette transporter that confers resistance to drugs and mediates the transport of organic anions. MRP1 has a core structure of two membrane spanning domains (MSDs) each followed by a nucleotide binding domain. This core structure is preceded by a third MSD with five transmembrane (TM) helices, whereas MSD2 and MSD3 each contain six TM helices. We investigated the consequences of Ala substitution of 18 Pro residues in both the non-membrane and TM regions of MSD2 and MSD3 on MRP1 expression and organic anion transport function. All MRP1-Pro mutants except P1113A were expressed in human embryonic kidney cells at levels comparable with wild-type MRP1. In addition, five mutants containing substitutions of Pro residues in or proximal to the TM helices of MSD2 (TM6-Pro 343 , TM8-Pro 448 , TM10-Pro 557 , and TM11-Pro 595 ) and MSD3 (TM14-Pro 1088 ) exhibited significantly reduced transport of five organic anion substrates. In contrast, mutation of Pro 1150 in the cytoplasmic loop (CL7) linking TM15 to TM16 caused a substantial increase in 17␤-estradiol-17-␤-(D-glucuronide) and methotrexate transport, whereas transport of other organic anions was reduced or unchanged. Significant substrate-specific changes in the ATP dependence of transport and binding by the P1150A mutant were also observed. Our findings demonstrate the importance of TM6, TM8, TM10, TM11, and TM14 in MRP1 transport function and suggest that CL7 may play a differential role in coupling the activity of the nucleotide binding domains to the translocation of different substrates across the membrane.
The human MRP1 1 (gene symbol ABCC1) that was originally cloned from a multidrug-resistant small cell lung cancer cell line is an integral membrane protein that belongs to subfamily C of the ABC superfamily of transporter proteins (1) (2) (3) . The human ABCC subfamily contains nine MRP-related proteins (MRP1-6/ABCC1-6 and MRP7-9/ABCC10 -12), the cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7), and the sulfonylurea receptors SUR1 (ABCC8) and SUR2 (ABCC9) (4, 5) . All 12 ABCC members have a core four domain structure consisting of two MSDs (each containing 6 TM helices) and two NBDs configured MSD-NBD1-MSD-NBD2. The core structures of MRP1-3, -6, and -7, as well as SUR1 and SUR2 are connected by a cytoplasmic loop, CL3 (or L o ) to a fifth domain, an NH 2 -terminal MSD consisting of 5 TM helices. This third MSD is the major structural feature that distinguishes these five domain, 17-TM helix proteins from CFTR, MRP4, -5, -8, and -9 (1, 3, 4, 6 ). The precise physiological functions of all ABCC proteins are not yet fully understood, although several are known to be important in certain genetic disorders. For example, mutations in MRP2 (ABCC2) are responsible for Dubin-Johnson syndrome, a form of congenital conjugated hyperbilirubinemia (7) , and mutations in CFTR (ABCC7) cause cystic fibrosis (8) .
Increased expression of MRP1 has been detected in drugresistant tumor cell lines and tumor tissues, and MRP1 has been demonstrated to mediate ATP-dependent cellular efflux of a wide variety of anticancer drugs and other xenobiotics such as antimony and arsenic-centered oxyanions (3, 9) . MRP1 has also been shown to transport a broad spectrum of organic anions including oxidized and reduced glutathione (GSSG and GSH) as well as anionic GSH, glucuronide, and sulfate conjugates (3, 10 -13) . Endogenous organic anion substrates of MRP1 include the cysteinyl leukotriene LTC 4 and the conjugated estrogens E 2 17␤G, E 1 3SO 4 , and dihydroepiandrosterone sulfate (11, 14 -18) . Exogenous organic anions such as the folic acid analog, MTX, and conjugated metabolites of the carcinogens, aflatoxin B 1 and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, are also substrates of MRP1 (3, 19 -21) . MRP1 is expressed in most human tissues, and studies of mice in which the Mrp1 gene has been disrupted have demonstrated that this transporter has a role in inflammation and detoxication (3, 22) .
One approach toward understanding the molecular details of the transport mechanism of MRP1 is to identify the amino acid residues critical for its activity by functional analysis of MRP1 mutants created using site-directed mutagenesis. For example, previous studies have identified a number of aromatic, polar, and charged amino acids in or proximal to the TM helices in both MSD2 (amino acids 323-601) and MSD3 (amino acids 972-1248) that play an important role in determining MRP1 transport activity and substrate specificity (23) (24) (25) (26) (27) (28) (29) (30) . Other studies have shown that Ala substitution of Cys residues in these domains as well as the cytoplasmic and extracytoplasmic regions of MRP1 do not appear to have major effects on its transport function (31) .
Sequence analyses have shown that Pro residues are more frequently found in TM ␣-helices of ion channels and transporters than in ␣-helices of water-soluble proteins (32) . Because their backbone N is not available for intrahelical H-bonding, and because of steric constraints caused by their ring structure, Pro residues may introduce "kinks" in TM ␣-helices, and a role for such Pro residues in substrate binding and/or translocation has been proposed for a number of membrane proteins (32) (33) (34) (35) (36) (37) . Non-membrane associated Pro residues have also been shown to be important for the function of certain ion channels and transporters (38) . In a previous study, we replaced 12 Pro residues in MSD1 and CL3 of MRP1 with Ala and found that while several of the resulting mutants showed reduced levels of MRP1 expression, the substitutions had little or no effect on LTC 4 and E 2 17␤G transport (39) . These findings are consistent with an interpretation that MSD1 is not critical for conjugated organic anion transport but probably has a role in the stable expression of MRP1 in mammalian cell plasma membranes. In the present study, we have extended this earlier work by investigating the role of the 18 Pro residues that reside in both the non-membrane and TM regions of MSD2 and MSD3, by examining the consequences of replacing these residues with Ala on the expression and function of MRP1. Many of these Pro residues are highly conserved in other human ABCC family members and MRP1 orthologs in other species (Table I) . Thus, the findings of our study may have implications for the structure-function analysis of other ABCC proteins.
We found that all but one of the singly substituted MRP1 Pro mutants (P1113A) could be expressed in HEK cells at levels comparable with the wild-type protein. In addition, five mutants containing substitutions of Pro residues predicted to be in or proximal to the TM helices of MSD2 (TM6-Pro 343 , TM8-Pro 448 , TM10-Pro 557 , and TM11-Pro 595 ) and MSD3 (TM14-Pro 1088 ) exhibited significantly reduced transport of five structurally diverse organic anion substrates of MRP1, whereas TM9 mutant P478A showed a selective reduction in LTC 4 and GSH transport and an increase in E 2 17␤G, E 1 3SO 4 , and MTX transport. Unexpectedly, a mutant containing a substitution of Pro 1150 predicted to be in the cytoplasmic loop (CL7) linking TM15 to TM16 showed markedly increased levels of E 2 17␤G and MTX transport, whereas transport of other organic anions was reduced or unchanged. The altered transport activity of P1150A was associated with significant changes in the ATP dependence of E 2 17␤G but not LTC 4 transport, suggesting that CL7 may play a differential role in coupling the activity of the MRP1 NBDs to the translocation of different substrates across the membrane.
EXPERIMENTAL PROCEDURES
Materials- [6,7- 3 H]E 2 17␤G (55 Ci mmol Ϫ1 ), [6, Vector Construction and Site-directed Mutagenesis-Pro mutations in MRP1 were generated using the QuikChange™ site-directed mutagenesis kit (Stratagene, La Jolla, CA). The template for mutagenesis of Pro residues in MSD2 was prepared by cloning a 1.9-kb BamHI/SphI fragment (containing nucleotides 841-2701 encoding amino acids 281-900) from pcDNA3.1(Ϫ)-MRP1 K into pBluescriptSK(ϩ) (Stratagene, La Jolla, CA) into which a SphI site had been introduced into the multiple cloning site (24) . The template for mutagenesis of Pro residues in MSD3 was prepared by cloning a 2-kb XmaI fragment (containing nucleotides 2337-4322 encoding amino acids 780 -1440) from pcDNA3.1(Ϫ)-MRP1 K into pGEM-3Z (Promega, Madison, WI) (23) . Proline substitutions were generated in the pBluescriptSK(ϩ) and pGEM-3Z plasmids above according to the manufacturer's instructions with the following mutagenic primers (substituted nucleotides are underlined): MSD2 Pro mutants, P323A, 5Ј-GTG TTA TAC AAG ACC TTT GGC GCC TAC TTC  CTC ATG AGC-3Ј; P343A, 5Ј-G ATG ATG TTT TCC GGG GCG CAG  ATC TTA AAG TTG C-3Ј; P359A, 5Ј-G AAT GAC ACG AAG GCC GCA  GAC TGG CAG GG-3Ј; P448A, 5Ј-G ATC TGG TCA GCC GCC CTG  CAA GTC ATC CTT GC-3Ј; P464A, 5Ј-G CTG AAT CTG GGC GCT TCC  GTC CTG GCT GG-3Ј; P478A, 5Ј-G GTC CTC ATG GTG GCC GTC AAT  GCT GTG-3Ј; P557A, 5Ј-CC TGG GTC TGC ACG GCC TTT CTG GTG  GCC-3Ј; P595A, 5Ј-C AAC ATC CTC CGG TTT GCC CTG AAC ATT  CTC C-3Ј; P600A, 5Ј-CCC CTG AAC ATT CTC GCG ATG GTC ATC TrEMBL entries P33527 (MRP1/ ABCC1), O15438 (MRP3,/ABCC3), Q92887 (MRP2,/ABCC2), O95255 (MRP6/  ABCC6), Q09428 (SUR1/ABCC8), O60706 (SUR2/ABCC9), Q8NHX7 (MRP7/ABCC10), O15439 (MRP4/ABCC4), O15440 (MRP5/ABCC5), and  P13569 (CFTR/ABCC7).   Position  MRP1  MRP3  MRP2  MRP6  SUR1  SUR2  MRP7  MRP4  MRP5  CFTR AGC AGC-3Ј; and MSD3 Pro mutants B P1003A, 5Ј-C TGG ACT GAT  GAC GCC ATC GTC AAC GGG-3Ј; P1060A, 5Ј-C CTG CGG TCA GCC  ATG AGC TTC-3Ј; P1068A, 5Ј-C TTT GAG CGG ACC GCG AGT GGG  AAC C-3Ј; P1088A, 5Ј-C TCC ATG ATC GCG GAG GTC ATC-3Ј;  P1113A, 5Ј-CTG CTG GCC ACG GCC ATC GCC GCC-3Ј; P1120A,  5Ј-GCC ATC ATC ATC GCG CCC CTT GG-3Ј; P1121A, 5Ј-C ATC ATC  ATC CCG GCG CTT GGC CTC ATC-3Ј; P1150A, 5Ј-G GTC AGC CGC  TCC GCG GTC TAT TCC C-3Ј; P1191A, 5Ј-C CAG AAG GCC TAT TAC  GCT AGC ATC GTG GCC AAC-3Ј; P1120A/P1121A, 5Ј-C GCC ATC  ATC ATC GCA GCG CTT GGC CTC ATC TAC TTC-3Ј . After confirming all mutations by sequencing or diagnostic restriction enzyme digests, the 1-kb BamHI/Bsu36I fragment (MSD2 Pro mutants) and the 1.3-kb BsmBI/EcoRI fragment (MSD3 Pro mutants) were subcloned back into pcDNA3.1(Ϫ)-MRP1 K , and the fragments in the full-length constructs were sequenced once again.
Transfections of MRP1 Expression Vectors in Human Embryonic
Kidney Cells-Wild-type and mutant pcDNA3.1(Ϫ)-MRP1 K expression vectors were transfected into SV40-transformed human embryonic kidney cells (HEK293T). For membrane vesicle preparations, ϳ7 ϫ 10 6 cells were seeded per 15-cm dish and transfected 24 h later with 16 g of plasmid DNA using FuGENE 6 (Roche Diagnostics) according to the manufacturer's instructions. After 60 h, the HEK293T cells were harvested, and membrane vesicles were prepared as described previously (40) . Empty vector and vector containing the wild-type cDNAs were included as controls in all experiments. Transfections were also carried out with a second independently generated clone of each mutant so that clonal variation could be excluded as an explanation for any changes in expression levels and/or transport activities observed.
Measurement of MRP1 Protein Levels in Transfected Cells-The levels of wild-type and mutant MRP1 proteins were determined by immunoblot analysis of membrane protein fractions from transfected cells essentially as described (41) . Proteins were resolved on a 6 -7% polyacrylamide gel and electrotransferred to Immobilon™ P membrane (Millipore, Bedford, MA). Blots were blocked with 4% (w/v) skim milk powder for 1 h followed by incubation with the human MRP1-specific monoclonal antibody QCRL-1 (diluted 1:10,000) (42, 43) . After washing, blots were incubated with horseradish peroxidase-conjugated goat antimouse antibody (Pierce) followed by application of Renaissance chemiluminescence blotting substrate (PerkinElmer Life Sciences) and exposed to film. Relative levels of MRP1 protein expression were estimated by densitometric analysis using a ChemiImager™ 4000 (Alpha Innotech, San Leandro, CA). To confirm equal protein loading of the gel lanes, the blots were also stained with Amido Black.
MRP1-mediated Transport by Membrane Vesicles-Membrane vesicles were prepared from transiently transfected HEK293T cells, and ATP-dependent transport of 3 H-labeled substrates by the membrane vesicles was measured using a rapid filtration technique as described previously (40) . Briefly, LTC 4 transport assays were performed at 23°C in a 50-l reaction containing 50 nM LTC 4 (40 nCi per reaction), 4 mM ATP, 10 mM MgCl 2 , an ATP-regenerating system (10 mM creatine phosphate, 100 g ml Ϫ1 creatine kinase), and 2 g of vesicle protein in transport buffer (50 mM Tris-HCl, 250 mM sucrose, pH 7.4). Control uptake assays contained 4 mM AMP, and the regenerating system was omitted. Uptake was stopped at the desired time by rapid dilution in ice-cold buffer, and then the reaction was filtered through glass-fiber filters presoaked in transport buffer. Radioactivity was quantitated by liquid scintillation counting. All data were corrected for the amount of [ 3 H]LTC 4 that remained bound to the filter, which was usually Ͻ10% of the total radioactivity. Transport in the presence of AMP was subtracted from transport in the presence of ATP to determine ATP-dependent LTC 4 uptake. All transport assays were carried out in triplicate, and results are expressed as means (ϮS.D.). Uptake of [ 3 H]E 2 17␤G was measured in a similar fashion, except that membrane vesicles (2 g of protein) were incubated at 37°C in a total reaction volume of 50 l containing 400 nM E 2 17␤G (40 nCi per reaction) and the components as described for LTC 4 transport. [ 3 H]E 1 3SO 4 uptake was performed at 37°C in a 50-l total reaction volume containing membrane vesicles (2 g of protein), 300 nM E 1 3SO 4 (100 nCi per reaction), in the presence of 3 mM GSH and 10 mM dithiothreitol and the same components described above (16, 44) . Apigenin-stimulated [ 3 H]GSH uptake was also measured by rapid filtration with membrane vesicles (20 g of protein) incubated at 37°C for 20 min in a 60-l reaction volume with 100 M [ 3 H]GSH (120 nCi per reaction) and 30 M apigenin (13) . To minimize GSH catabolism by ␥-glutamyltranspeptidase during transport, membranes were preincubated with 0.5 mM acivicin for 10 min at 37°C prior to measuring [ 3 H]GSH uptake. [ 3 H]MTX uptake was performed at 37°C for 20 min in a 50-l total reaction volume containing membrane vesicles (10 g of protein), 100 M MTX (200 nCi per reaction), and the same components described above (26, 45) (9) .
Confocal Microscopy-HEK293T cells transfected with the MRP1 constructs were seeded at 3.5 ϫ 10 5 cells per well in a 6-well plate on coverslips coated with 0.1% gelatin in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Forty-eight hours later, the coverslips were washed with PBS, and cells were fixed with 4% paraformaldehyde and permeabilized by adding 0.2% Triton X-100 in PBS. The coverslips were incubated with MRP1-specific mAb QCRL-3 (diluted 1:2,500 in 0.1% Triton X-100/PBS containing 10 g ml Ϫ1 RNase A and 1% bovine serum albumin) for 60 min (41, 42) . The coverslips were then incubated with Alexa Fluor 488 anti-mouse IgG (HϩL) (FabЈ) 2 fragment in 0.1% Triton X-100/PBS containing 2 g ml Ϫ1 propidium iodide and then placed on slides containing 1 drop of Antifade Solution (Molecular Probes, Inc., Eugene, OR). Cells were examined using a Leica TCS SP2 MS multiphoton system confocal microscope (Leica Microsystems, Heidelberg, Germany) as before (39) .
Photolabeling of MRP1 with [ 3 H]LTC 4 -Membrane proteins were photolabeled with [
3 H]LTC 4 essentially as described (40) . Briefly, membrane vesicles prepared from transfected cells (70 g of protein in a final volume of 50 l) were incubated with [ 3 H]LTC 4 (0.08 -0.1 Ci; 200 nM) and 10 mM MgCl 2 for 30 min at room temperature and then frozen in liquid nitrogen. Samples were then alternately irradiated at 302 nm for 1 min using a CL-1000 UV cross-linker (DiaMed, Mississauga, Ontario, Canada) and snap-frozen in liquid N 2 10 times. Radiolabeled proteins were resolved by SDS-PAGE and processed for autoradiography. After drying, the gel was exposed to X-Omat film for 2 days at Ϫ70°C. Relative levels of photolabeling were estimated by densitometric analysis as before. P]ATP (1 Ci). After 5 min on ice, the samples were UV cross-linked at 302 nm in a 96-well plate for a further 8 min, washed twice, and then solubilized in Laemmli buffer and subjected to SDS-PAGE. After drying, the gel was exposed to film for 1 h. (48) . Membrane vesicles prepared from untransfected HEK cells were included as a negative control. Reactions were terminated by the addition of ice-cold Tris-EGTA buffer (50 mM Tris-HCl, pH 7.4, 0.1 mM EGTA, 5 mM MgCl 2 ) and then centrifuged at 21,000 ϫ g for 15 min at 4°C. Resuspended membrane proteins were transferred to a 96-well plate and exposed to UV light at 302 nm on ice for 8 min. Membrane vesicles were then solubilized in Laemmli buffer and subjected to SDS-PAGE. After drying, the gel was exposed to film for 12-24 h.
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RESULTS
Expression Levels and Transport Activities of MRP1 Mutants Containing Ala Substitutions of MSD2 Pro Residues-Nine
Pro residues predicted to be in MSD2 of MRP1 (Fig. 1A) were individually replaced with Ala by site-directed mutagenesis, and the mutant proteins were expressed in HEK293T cells. Immunoblotting indicated that all nine MSD2 Pro mutants were expressed at levels that ranged from 50 to 94% those of wild-type MRP1, indicating that none of these Pro residues are critical for MRP1 expression in mammalian cells (Fig. 1B) .
To determine whether replacing the MSD2 Pro residues with Ala affected the function of MRP1, the ability of the nine mutants to transport five structurally diverse organic anion substrates of MRP1 was determined. [ 3 H]LTC 4 uptake assays were performed with membrane vesicles prepared from HEK cells expressing the MSD2 Pro 3 Ala mutants, and levels of ATP-dependent uptake (after normalization to take into account differences in MRP1 protein expression levels) are shown in Fig. 2A . Thus, relative to wild-type MRP1, [ 3 H]LTC 4 uptake by the MSD2 mutants P323A and P359A was moderately reduced (by ϳ25%), whereas uptake by the P343A, P448A, P478A, P557A, and P595A TM mutants was substantially reduced (by 55-70%). [ 3 H]LTC 4 uptake by the P464A and P600A mutants was comparable with wild-type MRP1 ( Fig. 2A) .
[ 3 H]E 2 17␤G uptake assays using membrane vesicles prepared from cells expressing the MSD2 Pro mutants were also performed. As shown in Fig. 2B , ATP-dependent uptake levels of this substrate by mutants P323A and P359A relative to wild-type MRP1 were moderately reduced (by ϳ30%), whereas uptake by mutants P343A, P448A, P557A, and P595A was substantially reduced (by 75-90%), and uptake by the P478A mutant was increased 1.5-fold. In contrast, as observed for
3 H]E 2 17␤G uptake by the P464A and P600A mutants was comparable with wild-type MRP1.
To determine whether the Pro to Ala substitutions in MSD2 affected the transport of other MRP1 substrates, levels of MTX, GSH, and E 1 3SO 4 uptake in inside-out membrane vesicles were determined. Relative to wild-type MRP1, [ 3 H]MTX uptake by the P323A and P359A mutants was moderately reduced (by 30 -40%), whereas uptake levels of the P343A, P448A, P557A, and P595A mutants were substantially reduced (by 75-90%). In contrast, [ 3 H]MTX uptake by the P464A and P478A mutants was moderately increased by ϳ30% relative to wild-type MRP1, whereas uptake by the P600A mutant was comparable with wild-type MRP1 (Fig. 2C) .
GSH transport was measured in the presence of apigenin (30 M), which previous studies have shown markedly enhances the uptake of this tripeptide by MRP1, thereby allowing more accurate quantitation (13, 47) . Relative to wild-type MRP1, GSH uptake by six of the nine MSD2 Pro mutants (P323A, P343A, P448A, P478A, P557A, and P595A) was substantially reduced (60 -93%), whereas GSH uptake levels by the P359A, P464A, and P600A mutants were comparable with wild-type MRP1 (Table II) . GSH-stimulated [ 3 H]E 1 3SO 4 uptake by the MSD2 Pro mutants was also measured and found to be moderately reduced in the P343A and P448A mutants (by 30 -40%) and substantially reduced in the P557A and P595A mutants (by 75-85%). In contrast, levels of [ 3 H]E 1 3SO 4 uptake by the P478A mutant were increased 1.5-fold, and those of the P323A, P359A, P464A, and P600A mutants were comparable with wild-type MRP1. These results, together with the LTC 4 , E 2 17␤G, and MTX uptake data shown in Fig. 2 , are summarized in Table II replaced the nine Pro residues that are predicted to be in MSD3 of MRP1 with Ala as before (Fig. 3A) . Eight of these mutants were expressed in HEK cells at levels comparable with those of A, shown is a schematic diagram of a secondary structure of MRP1 with the positions of the MSD3 TM helices based on the bacterial MsbA crystal structures and an energy-minimized P-glycoprotein simulation (50) . The locations of the MSD3 Pro residues mutated in this study are highlighted, and the approximate boundaries of the TM helices are indicated by dashed lines. B, shown is a representative immunoblot of membrane vesicles prepared from HEK293T cells transfected with empty vector (pcDNA3.1(Ϫ)), wild-type (WT-MRP1), and mutant (P1003A, P1060A, P1068A, P1088A, P1113A, P1120A, P1121A, P1150A, and P1191A) MRP1 cDNAs. MRP1 proteins were detected with mAb QCRL-1, and relative levels of expression estimated by densitometry are indicated; equal protein loading was confirmed by Amido Black staining of the polyvinylidene difluoride membrane and is shown below the blot. TM6  ECL3  P359A   TM8  P448A   ECL4  P464A   TM9  P478A   TM10  P557A   TM11   P323A  P343A  P595A  P600A   LTC 4  75  35  75  40  100  45  35  30  100  E 2 17␤G  70  10  70  25  100  155  10  Ͻ5  100  MTX  60  20  70  20  135  125  25  10  100  GSH  40  35  100  15  100  20  Ͻ10  10  100  E 1 3SO 4  100  70  100  60  100  155  25  15  100 a The values shown are means of triplicate determinations in a single experiment and are representative of results obtained in 2-3 independent experiments (for details, see legend to Fig. 2 and text) . For clarity, numbers have been rounded to the nearest 5% and S.D. values (which were typically 15% or less) were omitted.
wild-type MRP1. The exception was P1113A which was expressed at levels that were ϳ20% those of wild-type MRP1. This finding suggests that Ala substitution of Pro 1113 (which is predicted to be located in ECL7 connecting TM14 to TM15) in some way impairs the expression or stability of MRP1 (Fig. 3B) . The electrophoretic mobility of the small amounts of Pro 1113 mutant protein present was comparable with wild-type MRP1, indicating that processing had occurred.
To determine whether Ala substitution of the nine MSD3 Pro residues affected MRP1 transport function, the uptake of five organic anions into membrane vesicles prepared from transfected cells was examined as before. As shown in Fig. 4A (Fig. 4B) .
[ 3 H]MTX uptake by the P1150A mutant was also dramatically increased (ϳ6-fold) whereas uptake of this antifolate by the remaining eight MSD3 Pro mutants was either moderately reduced (by 50 -60% for P1068A, P1088A, and P1120A) or comparable with wild-type MRP1 (P1003A, P1060A, P1113A, P1121A, and P1191A) (Fig. 4C) . To determine whether Ala substitution of Pro 1150 also affected the transport of other folic acid derivatives, [ 3 H]leucovorin uptake by the P1150A mutant was assessed. As shown in Fig. 4D Table III . Relative to wild-type MRP1, apigenin-stimulated GSH uptake by the P1068A, P1088A, and P1150A mutants was significantly reduced (by 50 -70%), whereas uptake by the other six MSD3 Pro CL6  TM14  P1088A   ECL7  P1113A   TM15  CL7   P1060A  P1068A  P1120A  P1121A  P1150A  P1191A   LTC 4  60  90  60  50  100  100  110  50  90  E 2 17␤G  65  50  55  45  90  60  70  220  90  MTX  80  80  40  45  100  50  85  620  100  GSH  80  95  50  30  120  140  80  35  100  E 1 3SO 4  75  75  90  50  120  90  80  65  60 a The values shown are means of triplicate determinations in a single experiment and are representative of results obtained in 2-3 independent experiments (for details, see legend to Fig. 4 and text) . For clarity, numbers have been rounded to the nearest 5% and S.D. values (which are typically 15% or less) were omitted. mutants was similar to wild-type MRP1 except for P1120A, which was 1.4-fold higher. GSH-stimulated E 1 3SO 4 uptake by the P1003A, P1060A, P1088A, P1150A, and P1191A mutants was moderately reduced (by 25-50%), whereas uptake of this sulfated estrogen by the other four MSD3 Pro mutants (P1068A, P1113A, P1120A, and P1121A) was comparable with wild-type MRP1.
Taken together, these results indicate that none of the 9 MSD3 Pro residues are critical for the transport function of MRP1. However, a substrate-selective role in transport activity may be played by both TM-associated ( ) might restore MRP1 expression by a compensatory change in structure (P1113A/P1120A and P1113A/P1121A); a third mutant, P1120A/P1121A, was also generated and included in these experiments. Expression levels of these double Pro mutants were determined in membrane proteins isolated from the transfected HEK cells by immunoblotting with mAb QCRL-1 as before (Fig. 5A) . The results show that the expression levels of the two Pro 1113 double mutants were reduced by more than 80% as was observed for the single P1113A mutant. On the other hand, the third mutant, P1120A/P1121A, was expressed at levels that were at least 60% those of wild-type MRP1. These results indicate that mutation of Pro 1113 to Ala is consistently associated with a marked reduction in MRP1 protein expression levels that cannot be compensated for by additional Pro substitutions nearby. Despite the decreased expression levels of the three P1113A containing MRP1 mutants, indirect immunofluorescence confocal microscopy of intact transfected HEK293T cells showed that all of the Pro 1113 mutants were correctly routed to the plasma membrane as was the P1120A/P1121A mutant (Fig. 6) .
To gain further insight into the mechanism by which the Ala substitution of Pro 1113 results in decreased MRP1 expression, steady state MRP1 mRNA levels of the three double mutants and the single P1113A mutant were determined by Northern blot analysis of total RNA isolated from transfected cells expressing the mutant proteins (Fig. 5B) . Levels of P1113A, P1113A/P1120A, P1113A/1121A, and P1120/P1121A mutant MRP1 mRNAs were found to be comparable with those of wild-type MRP1 mRNA, suggesting that the low expression of MRP1 mutants containing a Pro 1113 3 Ala substitution is caused by some event that occurs after transcription.
FIG. 5. Expression levels of MRP1 mutants containing an Ala substitution of Pro
1113
. A, membrane vesicle proteins (1 and 2 g) prepared from HEK293T cells transfected with empty vector (pcDNA3.1(Ϫ)), wild-type (WT-MRP1), and mutant (P1113A, P1113A/ P1120A, P1113A/P1121A, and P1120A/P1121A) MRP1 cDNAs were immunoblotted, and MRP1 was detected with mAb QCRL-1. The polyvinylidene difluoride membrane was also stained with Amido Black to confirm equal loading of proteins. B, Northern blot analysis of total RNA isolated from the transfected HEK cells described in A. Total RNA (5 g per lane) was separated on a formaldehyde-agarose gel and transferred onto a nylon membrane. The membrane was probed with a 32 P-labeled MRP1 1.8-kb EcoRI fragment that was hybridized with an mRNA of ϳ5.1 kb as expected for an MRP1 transcript encoded by the pcDNA3.1(Ϫ)-MRP1 k expression vector. The ethidium bromide-stained gel below the blot shows the 18 S and 28 S rRNA and confirms the relative RNA loading of the lanes. The apparent K m (E 2 17␤G) for the MSD3 P1150A mutant, which showed significantly enhanced E 2 17␤G transport, was decreased 4-fold (0.24 versus 1.02 M for wild-type MRP1). In contrast, the apparent K m (E 2 17␤G) value for P1088A was increased 1.4-fold (1.39 M). On the other hand, the V max(E217␤G) values of P1150A and P1088A (160 and 165 pmol mg Ϫ1 min Ϫ1 , respectively) were comparable with wild-type MRP1 (176 pmol mg Ϫ1 min Ϫ1 ). Thus, the overall E 2 17␤G transport efficiency of P1150A was enhanced ϳ4-fold whereas that of P1088A was reduced by 35%, largely because of changes in the apparent uptake affinity of the mutant proteins for this conjugated estrogen.
Photolabeling 4 , whereas the other mutations caused no or only a moderate reduction in photolabeling compared with wild-type MRP1.
ATP Dependence of LTC 4 and E 2 17␤G Transport by MRP1-P1150A-To explore further the mechanism of enhanced E 2 17␤G transport by the P1150A mutant, the ATP dependence of E 2 17␤G uptake by membrane vesicles expressing this mutant MRP1 was investigated by measuring initial rates of up- take of this conjugated organic anion at different ATP concentrations (Fig. 8A) . The ATP dependence of LTC 4 transport by P1150A was also measured for comparison (Fig. 8B ). In the case of E 2 17␤G transport (Fig. 8A) , the K m(ATP) and V max values were 108 M and 295 pmol mg Ϫ1 min Ϫ1 and 483 M and 142 pmol mg Ϫ1 min Ϫ1 for P1150A and wild-type MRP1, respectively. In the case of LTC 4 transport (Fig. 8B) , the K m(ATP) and V max values were 97 M and 90 pmol mg Ϫ1 min Ϫ1 and 109 M and 170 pmol mg Ϫ1 min Ϫ1 for P1150A and wild-type MRP1, respectively. Thus the MRP1-P1150A mutant showed a significantly lower (nearly 5-fold) K m (higher apparent affinity) for ATP than wild-type MRP1 when supporting transport of E 2 17␤G. In contrast, when supporting LTC 4 transport, the K m(ATP) of P1150A and wild-type MRP1 were similar.
8-Azido-[␣-32 P]ATP Binding and Orthovanadate-induced Trapping of 8-Azido-[␣-
32 P]ADP by MRP1-P1150A-To investigate further the ATP binding and hydrolysis properties of the MRP1-P1150A mutant, we used a 32 P-labeled photoactivable nucleotide analog to evaluate its relative ability to bind ATP. As shown in Fig. 9A , at 4°C 8-azido-[␣-
32 P]ATP photolabeled a 190-kDa protein corresponding to MRP1 in membrane proteins prepared from both wild-type and P1150A mutant MRP1-transfected cells. The intensity of labeling of the wild-type and mutant MRP1 proteins was similar, indicating a comparable level of ATP binding by the two proteins. In contrast, orthovanadate-induced trapping of 8-azido-[␣- 32 P]ADP at 37°C by the P1150A mutant was markedly reduced compared with wild-type MRP1 (Fig. 9B) . This indicates that although mutation of Pro 1150 does not appear to affect binding of ATP, it may reduce the ability of MRP1 to hydrolyze ATP. This finding was confirmed by using an alternate nucleotide trapping agent, BeF x (48).
DISCUSSION
The unique chemical and biophysical properties of Pro residues and their important function in many membrane transporter and channel proteins prompted us to investigate the role of this amino acid in the structure and function of human MRP1. In a previous study, we investigated the consequences of substituting Ala for the 12 Pro residues in the ϳ280 amino acids that comprise MSD1 and the CL connecting it to MSD2. Several of the MSD1 Pro mutations caused a substantial reduction in MRP1 expression, suggesting that MSD1 is important for the stable expression of MRP1 in mammalian cell membranes (39) . In the present study, we found that the MRP1 mutant containing an Ala substitution of Pro 1113 in MSD3 was also poorly expressed. According to most topological models of MRP1, Pro 1113 is located in the relatively short ECL that connects TM14 to TM15. Consequently, as suggested previously for Pro 104 (39) , Pro 1113 may facilitate insertion of TM14 and TM15 into the membrane during biosynthesis. The absence of Pro 104 or Pro 1113 may cause misfolding and destabilization of MRP1, leading to its enhanced degradation and low expression levels. Consistent with this conclusion is the observation that incubation of P1113A-transfected HEK293T cells at a reduced temperature (30°C) significantly enhances the levels of plasma membrane expression of the P1113A mutant protein (results not shown). With relatively few amino acids predicted to be in the ECL between TM14 and TM15, it may be that these two helices form a closely interacting structure. However, the structural change introduced by substitution of Pro 1113 in MRP1 could not be compensated for by introducing another structural change by replacing nearby Pro residues in TM15 (Pro 1120 and Pro 1121 ) because the double mutants P1113A/P1120A and P1113A/ P1121A were also poorly expressed. Nevertheless, despite their low levels of expression, the Pro 1113 mutants could all be detected at the plasma membrane of the transfected cells. Given the very substantial structural change that would be introduced by simultaneous substitution of two adjacent Pro residues (33, 49) , it is somewhat surprising that the TM15 double Pro mutant P1120A/P1121A was expressed at levels comparable with wild-type MRP1, and its transport activity was also similar to the wild-type protein (results not shown). However, these Pro residues are predicted to be located at the NH 2 -proximal end of TM15 in the outer leaflet of the membrane bilayer which may make it less likely for any structural changes introduced into TM15 by their substitution to disrupt the interhelical interactions that are presumed to occur between TM15 and other TM helices of MRP1. In addition, according to our current model of MSD2 and MSD3 of MRP1 (which is based on the crystal structures of two bacterial MsbA transporters and an energy minimized P-glycoprotein simulation (50)), amino acids in this region of TM15 are not predicted to be directly in the substrate translocation pathway.
In our previous study, we found that single Ala substitutions of MSD1 Pro residues had little effect on the organic anion transport activity of MRP1 (39) . In contrast, Ala substitutions of the Pro residues of MSD2 had variable, and in some cases profound, effects on MRP1 transport activity. For example, Pro 3 Ala substitutions at positions 343 (TM6), 448 (TM8), 557 (TM10), and 595 (TM11) caused a marked decrease in, or eliminated, transport of at least four of the five organic anions tested, whereas Ala substitution of MSD2 Pro residues at positions 359 (in ECL3), 464 (in ECL4), and 600 (at the TM11-cytosol interface) had little or no effect. Between these two extremes of transport activity were mutants P323A and P478A. Replacement of Pro 323 at the TM6 membrane-cytosol interface with Ala caused a significant and relatively specific loss of GSH transport, whereas Ala substitution of Pro 478 (TM9) was associated with a substantial loss of LTC 4 and GSH transport on the one hand, and a moderate increase in E 2 17␤G, MTX, and E 1 3SO 4 transport on the other. The partial and substrateselective alterations in transport activity observed for the P323A and P478A mutants provide evidence that although these Pro residues are not essential for function, they may be involved in some substrate-specific interactions with the transporter.
The almost total loss of MRP1 transport activity of the MSD2 TM mutants P343A, P448A, P557A, and P595A does not distinguish between a structural or dynamic role for these Pro residues but does confirm that these highly conserved residues are required for transport. However, all but one of these mutants (P595A) could still be labeled with [
3 H]LTC 4 , indicating that if the Pro substitutions caused any structural changes, they did not disrupt the binding site for this substrate. Predicted to be located well within the membrane bilayer, Pro 343 (TM6), Pro 448 (TM8), Pro 557 (TM10), and Pro 595 (TM11) may introduce a kink into the ␣-helix between the segments preceding and following the Pro residue. Such so-called Pro-kink motifs can occur because of the inability of the Pro residue to form intrahelical hydrogen bonds. This lack of hydrogen bond donor activity in turn can result in a greater flexibility of a TM helix, which may allow it to respond conformationally to specific interactions with substrate or to function in the propagation of conformational changes from one protein domain to another (33) . Thus, a Pro residue could act as a "switch" between the different conformations adopted by the protein in different steps of its catalytic or transport cycle. Additionally or alternatively, Pro-kinks may contribute to a narrowing of the ends of a substrate translocation pathway and, in this way, contribute to the architecture of the "chamber" through which substrates are effluxed out of the cell. However, it has been established that the number of energetically favored conformations available to a kinked ␣-helix and its preferred bend angle can be altered by the residues surrounding the Pro (either within the same helix and/or in neighboring helices), and this alteration can be reflected in the functional properties of the mutants (37, 51, 52 (37) . It may be that the loss of these Pro residues modifies the architecture of the MRP1 substrate translocation pathway directly by changing the geometry of the TMs in which they are located and/or indirectly by causing a shift in overall TM helix packing.
Finally, the functional importance of the four MSD2 TM Pro residues at positions 343, 448, 557, and 595 is consistent with their location in the same TM helices (TM6, TM8, TM10, and TM11, respectively) that contain other amino acids shown in previous studies to be important for MRP1 drug binding and/or transport activity (24, 26, 50, 53, 54) . However, of these four MSD2 TM Pro mutants that display a global and substantial loss of transport activity, only one of them (P595A) showed a complete loss of photolabeling by LTC 4 and a major decrease in uptake affinity for this substrate. Similarly, non-conservative substitutions of the nearby Phe 594 (50) and Arg 593 (54) 2 residues in TM11, which also caused a global loss of MRP1 transport activity, eliminated LTC 4 photolabeling. These observations point to a particularly critical role for this region of TM11, together with charged residues in TM6 (26) , in the high affinity binding of LTC 4 and likely other substrates as well.
In contrast to the MSD2 mutants, none of the nine MSD3 Pro mutants examined showed a comparable global decrease in transport activity, although Ala substitution of Pro 1088 (at the membrane cytosol interface of TM14) and to a lesser extent Pro 1003 (in ECL6) did cause a significant reduction in the transport of all five organic anion substrates tested. The significantly reduced transport activity of the P1088A mutant, together with our previous findings that non-conservative mutations of polar residues in the same region of TM14 alter MRP1 transport activity, confirm that the TM14-cytosol interface is a particularly important region for MRP1 activity (25, 29) . 3 Other MSD3 Pro mutants showed more substrate-selective changes in transport activity. For example, Ala substitution of Pro 1120 (in TM15) caused a moderate and selective loss of E 2 17␤G and MTX uptake. In contrast, the relative transport activities of the single Pro 1113 (in ECL7) and Pro 1121 (in TM15) mutants were comparable with those of wild-type MRP1 except for a moderate and selective loss of E 2 17␤G transport activity observed for the latter mutant.
Mutation of Pro residues in the predicted CLs of MSD3 also resulted in substrate-selective changes in transport activity. These intracellular domains (and the comparable domains in MSD2) are extensively ␣-helical but are presumably not part of the substrate translocation pathway through the membrane bilayer. Ala substitution of Pro 1060 (in CL6) caused a moderate and selective loss of E 2 17␤G transport, and Ala substitution of Pro 1068 (in CL6) caused a moderate overall loss of organic anion transport except for E 1 3SO 4 transport, which remained comparable with wild-type MRP1. In current models of MRP1 (29, 50) , CL6 contains three ␣-helices, with the central helix flanked by Pro 1060 and Pro 1068 . The analogous helix in the bacterial transporter MsbA appears to be in contact with the NBD, and it has been proposed that it may be important for transduction of conformational changes that occur between the NBD and MSD following nucleotide binding and hydrolysis (55) . That structural changes are introduced into CL6 by replacement of Pro 1060 or Pro 1068 with Ala is evident from the loss of immunoreactivity of the P1060A and P1068A mutants with mAb MRPm5 which maps to amino acids 1063-1072. 4 However, the moderate changes in the transport properties of the P1060A and P1068A mutants, and the fact that mAb MRPm5 does not inhibit MRP1 transport activity, suggest that considerable mobility of this loop can be accommodated without loss of MRP1 activity.
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CL7 is also predicted to be extensively ␣-helical and, like CL6, contains two Pro residues. One of these, Pro 1191 , is located at the COOH-proximal end of CL7, and Ala substitution of this residue caused only a modest and selective loss of E 1 3SO 4 uptake. This suggests that the structural change introduced into this region of CL7 by mutation of Pro 1191 does not significantly alter binding or transport of organic anions by MRP1.
The second, more NH 2 -proximal CL7 Pro residue at position 1150, is located at the end of a putative ␣-helix that begins with TM15 and is predicted to extend well into the cytoplasm. The P1150A mutant showed a moderate but significant decrease in LTC 4 , GSH, and E 1 3SO 4 transport but, remarkably, also exhibited a substantial increase in E 2 17␤G and MTX transport. The decrease in LTC 4 transport caused by the P1150A mutation was associated with a 2.5-fold decrease in V max , whereas the increase in E 2 17␤G transport was associated with a 4-fold increase in uptake affinity (decreased K m ). These observations indicate that the structural change introduced by Ala substitution of Pro 1150 in some way selectively enhances the apparent uptake affinity of MRP1 for the glucuronidated estrogen while at the same time diminishes the efficiency of LTC 4 transport.
Intriguingly, the P1150A mutation also affected the apparent ATP dependence of organic anion transport in a substrateselective way. Thus, the P1150A mutation caused a 5-fold increase in apparent affinity (decreased K m ) for ATP and 2-fold increase in V max when supporting E 2 17␤G transport. However, for LTC 4 transport, the K m(ATP) of P1150A was unchanged, and a 2-fold decrease in V max was observed. Furthermore, whereas the P1150A mutant appeared to bind azido-ATP as well as wild-type MRP1, it showed substantially reduced vanadateand BeF-induced trapping of azido-ADP. We have shown previously that at 4°C, NBD1 is predominantly photolabeled by azido-ATP, whereas under trapping conditions at 37°C, the NBD2 is much more strongly labeled by azido-ADP than NBD1. Thus, our present observations suggest that the CL7 Pro 1150 mutation somehow compromises the ability of NBD2 to hydrolyze ATP and/or trap ADP in the presence of vanadate and BeF. This could contribute, at least in part, to the moderately reduced ability of the P1150A mutant to transport LTC 4 , because previous studies have indicated that ATP binding/ hydrolysis at NBD2 plays a dominant role in the transport of this substrate (46, 56) . However, it is not immediately obvious how reduced ATP binding/hydrolysis activity at NBD2 can be reconciled with the enhanced ability of the P1150A mutant to transport E 2 17␤G and MTX. One possibility is that ADP release from NBD2 of the P1150A mutant after hydrolysis is so rapid that the efficiency of vanadate-induced trapping of ADP is reduced, but this cannot explain the substrate-specific changes observed. A more likely explanation is that the Pro 1150 mutation has had a differential effect on the coupling of ATP binding and hydrolysis to the conformational changes involved in translocating LTC 4 compared with E 2 17␤G. Further studies are needed to distinguish among these and other possibilities.
MTX transport by the P1150A mutant was increased to an even greater extent than E 2 17␤G transport. Interestingly, however, transport of the related folate analog, leucovorin, remained comparable with that of wild-type MRP1. The chemical structures of leucovorin and MTX are very similar, differing only in the nature of three functional groups located in different regions of the molecules (Fig. 4D ). These structural differences are certain to affect the H-bonding capabilities of the two drugs, but whether or not they are related to the differing ability of the P1150A mutant to transport these two substrates awaits the availability of a more refined structure of MRP1.
Pro residues are significantly more abundant in MSD2 and MSD3 of MRP1 than in the corresponding regions of the more distantly related multidrug transporter P-glycoprotein (ABCB1) and the more closely related chloride channel, CFTR (ABCC7). Furthermore, in contrast to P-glycoprotein and CFTR, the Pro residues are not distributed symmetrically in the two core MSDs of MRP1. Earlier studies of CFTR and P-glycoprotein established that several Pro residues in or proximal to their TM helices were important for their function and/or expression (57, 58) . However, neither of the two functionally important Pro residues identified in P-glycoprotein are analogous to any of those mutated in our study of MRP1, indicating that Pro residues play different roles in these two multidrug transporters (57) . On the other hand, seven of the 18 MRP1 Pro residues studied here are conserved in CFTR, and mutations of three of them, Pro 99 , Pro 205 , and Pro 1021 (analogous to MRP1 TM residues Pro 343 , Pro 448 , and Pro 1121 ), are associated with loss of CFTR channel function (58, 59) . Indeed, there is also evidence that TM3 CFTR-Pro 205 is on the wateraccessible surface of the protein and forms a portion of the chloride channel lining (59). Our current model of MRP1 based on the crystal structures of the bacterial lipid transporter MsbA predicts that the analogous Pro 448 in TM8 also lines the substrate translocation pathway of MRP1 (50) and probably is also water-accessible, although this needs to be confirmed experimentally. Finally, it is worth noting that a conserved Trp residue is located within one helical turn of TM8 MRP1-Pro ) and has been shown to be important for the function of these two ABCC proteins (24, 59) . Previous biophysical and modeling studies of channel and transport proteins indicate that the solvent accessibility of a Trp residue in a TM ␣-helix would be diminished by an Ala substitution of a Pro residue located at either position i ϩ 3 or i ϩ 4 (60). Whether or not a change in water accessibility is directly related to the loss of function observed when either of these TM Trp or Pro residues in TM3 and TM8 of CFTR and MRP1, respectively, are mutated remains to be determined.
